Case series:infusion of cell

2 trials

Sponsors

The Second Affiliated Hospital of Soochow University, Nanjing Gulou Hosptial

Conditions

CD19 positive recurrent and refractory B cell malignanciesblood system malignant tumor

Unknown Phase

The clinical application of chimeric antigen receptor T cells in the treatment of CD19 positive recurrence of refractory b-cell source of blood system malignant tumor.

RecruitingChiCTR1800015226

The Second Affiliated Hospital of Soochow Universityblood system malignant tumor

Start: 2018-03-16Updated: 2018-03-19

Targeting CD19 chimeric antigen receptor gene modified autologous T cells (CD19 CAR-T) for the treatment of CD19 positive recurrent and refractory B cell malignancies

RecruitingChiCTR1800016584

Nanjing Gulou HosptialCD19 positive recurrent and refractory B cell malignancies

Start: 2018-07-01Updated: 2018-09-17